01—Abstract
Summary
Summary of the 10-K filed February 8, 2024. Cited figures are marked; the original filing is the authoritative source.
Corteva, Inc. reported net sales of $17.2 billiona for the fiscal year 2023, a slight decrease of 1% compared to the previous year, primarily attributed to a 10% volume decline partially offset by a 7% price increase and a favorable portfolio impact from acquisitions.
The company's operating EBITDA improved to $3.4 billionb, driven by strong price execution and productivity initiatives. Corteva successfully integrated two biologicals companies, Stoller and Symborg, in early 2023, enhancing its crop protection portfolio. The company returned approximately $1.2 billion to shareholders through share repurchases and dividends in 2023, reflecting a commitment to capital deployment.
Looking ahead to 2024, Corteva anticipates net sales between $17.4 billionc and $17.7 billion and operating EBITDA between $3.5 billion and $3.7 billion, indicating confidence in continued growth and operational efficiency. Significant emphasis was placed on innovation and sustainability, with increased investment in R&D to deliver differentiated solutions. The company continues to manage risks associated with regulatory approvals, supply chain dynamics, and evolving market conditions, while also navigating ongoing litigation related to legacy EIDP businesses, particularly concerning PFAS matters.
02—Key points
Key Highlights
- Net sales for fiscal year 2023 were $17.2 billion, a 1% decrease year-over-year, mainly due to lower volumes (down 10%) offset by price increases (up 7%) and portfolio impacts.
- Operating EBITDA improved to $3.4 billion, driven by price execution and productivity actions, despite lower volumes and cost/currency headwinds.
- Corteva completed the acquisitions of Stoller Group and Symborg, bolstering its Biologicals and microbiological technologies offerings in the Crop Protection segment.
- The company returned approximately $1.2 billion to shareholders in 2023 through share repurchases ($500 million) and dividends ($620 million).
- Corteva expects 2024 net sales to be in the range of $17.4 billion to $17.7 billion and Operating EBITDA between $3.5 billion and $3.7 billion.
- R&D expenses increased to $1.3 billion (8% of net sales) to support innovation and product pipeline development.
- The Seed segment saw a 5% increase in net sales to $9.5 billion, driven by a 13% price increase, while Segment Operating EBITDA grew 28% to $2.1 billion.
- The Crop Protection segment's net sales decreased by 9% to $7.8 billion due to lower volumes and currency impacts, with Segment Operating EBITDA down 18% to $1.4 billion.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 8, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $17.23B$17.45B | −1.3% |
| Cost of Revenue | $9.92B$10.44B | −4.9% |
| Gross Profit | $7.31B$7.02B | +4.1% |
| R&D Expenses | $1.34B$1.22B | +10.0% |
| SG&A Expenses | $3.18B$3.17B | +0.1% |
| Net Income | $735.00M$1.16B | −36.5% |
| EPS (Basic) | $1.04$1.59 | −34.6% |
| EPS (Diluted) | $1.03$1.58 | −34.8% |
| Shares Outstanding (Basic) | 709.00M720.80M | −1.6% |
| Shares Outstanding (Diluted) | 711.90M724.50M | −1.7% |
05—Questions
Frequently Asked Questions
What were Corteva's key financial results for fiscal year 2023?
Corteva reported net sales of $17.2 billion, a slight decrease of 1% from the prior year, primarily due to a 10% decline in volume, which was offset by a 7% price increase and favorable portfolio impacts. Operating EBITDA increased to $3.4 billion, driven by strong price execution and productivity initiatives.
How did the acquisitions of Stoller and Symborg impact Corteva?
Corteva acquired Stoller Group and Symborg in March 2023, expanding its portfolio in the Biologicals and microbiological technologies space within the Crop Protection segment. These acquisitions are expected to complement evolving farming practices and contribute to future growth.
What is Corteva's outlook for 2024?
Corteva projects 2024 net sales to be in the range of $17.4 billion to $17.7 billion and Operating EBITDA between $3.5 billion and $3.7 billion. This outlook reflects confidence in the constructive global agriculture outlook and the company's strategic priorities.
How is Corteva managing its capital allocation?
In 2023, Corteva returned approximately $1.2 billion to shareholders through share repurchases ($500 million) and dividends ($620 million). The company continues to prioritize deploying capital with discipline, balancing investments, growth opportunities, and shareholder returns.
What are the main risks Corteva highlighted in its filing?
Key risks include navigating complex and evolving regulatory environments for seed and crop protection products, managing supply chain disruptions and input cost volatility, intense competition, potential impacts of climate change and weather, and ongoing litigation related to legacy environmental liabilities (PFAS matters). Cybersecurity is also noted as a risk, though no material impact has been experienced to date.
06—Continue